
20 key habits highly productive managers swear by
Below, 20 Fast Company Executive Board members share their insights on other tried-and-true habits every successful executive should practice regularly.
1. BUILD A ROUTINE THAT FITS YOUR PERSONAL WORK STYLE.
You don't have to wake up at 5 a.m., meditate for an hour, and run a marathon before breakfast to be a great leader. Some people work best at 6 a.m.—others at midnight. The real habit is ignoring the hype and building a routine that actually fits how you work best, not how Instagram says you should. – Chris Erhardt, Chris Erhardt
2. SPEND YOUR TIME AND ENERGY WISELY.
Refuel throughout the day. Our brains are not machines that can operate at a steady pace indefinitely. Start with a good night's sleep, schedule in breaks, and make intentional choices about where to focus your time and energy. – Shani Harmon, Stop Meeting Like This
3. PREPARE A RECOVERY AND DISASTER PLAN.
Just as organizations create data recovery plans to tackle potential data disasters, successful leaders should be mindful of possible crises and prepare corresponding response plans. This way, sudden or unforeseen events won't interrupt workflows or drag operations down into inefficiency. – Alan Chen, DataNumen, Inc.
4. PROTECT A DAILY DISTRACTION-FREE TIME ZONE TO TACKLE HIGH-IMPACT TASKS.
Successful leaders prioritize deep work: setting aside focused, distraction-free time daily to tackle high-impact tasks. Protecting this time helps them think strategically, solve problems creatively, and maintain consistent productivity without burning out. – Scott Keever, Keever SEO
5. MAKE ROOM FOR YOUR TEAM TO THRIVE COLLECTIVELY.
Create space for others to thrive. Whether team or talent, it's important to give people ownership and trust their instincts. The right vibe, the right energy—it all starts with how you lead. – Shaun Fabos, Fab Factory Studios
6. CHECK EMAIL AFTER FINISHING A MORE CONSEQUENTIAL TASK.
Cultivate your strategic ignorance. Each day, I don't check email until I've completed my most consequential task. This way, I'm working on important tasks that merit executive attention instead of the urgent ones. A leader's productivity is measured by the opportunities seized, not the problems solved. Ignore more things. – Shayne Fitz-Coy, Sabot Family Companies
7. AVOID OVERLOADING YOURSELF WITH EXTRA WORK RESPONSIBILITIES.
The most successful leaders are ones who delegate. Delegation is crucial for talent growth and the development of your greater team. Leaders who delegate provide opportunities for their teams to take on more challenging work and develop new skills, ultimately building a stronger pipeline of future leaders. – Stan Gregor, Summit Financial
8. STAY IN YOUR OWN LANE.
One habit all great leaders share is relentless prioritization. Even if a task takes five minutes, if it's not your job, don't do it. Every small distraction pulls focus from what only you can do—setting direction, unblocking teams, and making high-leverage decisions. Delegate well and stay focused on impact. – Sezer Ovunc, Snapshot Reviews
9. GO FOR A WALK.
I make time to walk. Whether I do it alone or with others, it clears my head, sharpens my focus, and gets my creative thinking flowing. That active rhythm of movement and reflection helps me reset and stay productive. – Nicholas Wyman, IWSI America
10. CREATE A STRATEGY FOR COMPLETING WEEKLY GOALS.
Align your calendar with your strategic priorities. Being very intentional about where you spend your time indicates what's important to you. Make sure that your weekly rhythms are moving your goals forward. Bookend your week with planning sessions—use Monday morning to structure and prep, and Friday afternoon to audit, reflect, and make adjustments. – Rachel Kobetz, PayPal
11. SCHEDULE A 'NO MEETING WEDNESDAY.'
Protect your thinking time. We're all cramming in back-to-back meetings, and having time to just think has become a power move. We've started blocking space for strategy and reflection with something I call a 'no meeting Wednesday,' aimed at enabling the teams to have time to connect one-on-one and create. Ultimately, clarity and creativity happen when you step back, zoom out, and make room for it. – Kristin Russel, symplr
12. PUT YOUR DEVICES DOWN.
Take time out to reflect and plan. Just a few minutes each day to step back and think about what's working, what needs tweaking, and how things are moving toward your big goals can make a big difference. Adding a no-device focus time makes this habit even more powerful. It helps you stay focused on what truly matters and avoid getting lost in day-to-day tasks. – Krishnan Venkata, LatentView Analytics Corp.
13. FIND A WORKAROUND SOLUTION FOR WHAT DRIVES AND DRAINS YOU.
Identify your drivers and drainers and build your schedule accordingly. Some leaders thrive on constant travel, while others need a steady office presence to get their work done. Knowing yourself and your style makes it easier to stay productive, communicate with your team, and lead by example. – Caitlin MacGregor, Plum
14. LEAD WITH TRANSPARENCY.
Be transparent with your team. That's been my day-one approach to leadership because it works to empower and engage your workforce, and that's what promotes productivity. That said, transparency isn't just about providing basic updates; it's also about creating an environment that thrives on open communication where your employees feel like true stakeholders. – Steve Cox, Employ Inc.
15. TAKE SOME TIME AWAY FROM WORK.
Leaders need vacations, too. Burnout is real, and constant productivity isn't sustainable. The skills that got us here, like our drive and efficiency, won't keep us here without rest. True leadership requires vigilance, and that includes knowing when to step back, recharge, and return stronger. Rest isn't a luxury; it's a strategy for sustained impact. – Nisha Anand, Dream.Org
16. ASSESS YOUR CORE VALUES DAILY.
It's about being intentional with your time and energy. Start each day by reassessing your core values. Productivity stems from motivation, and nothing motivates me more than the passion of mission-driven work that aligns with my values. Consistently doing this builds stronger relationships and strengthens perseverance through challenges. – Larry Brinker Jr., BRINKER
17. ONLY FOCUS ON PROJECTS THAT MOVE THE NEEDLE.
Protect your time with intention. Success comes from the ability to focus on the right things. The most effective leaders protect their calendars, reflect often, and focus on what truly moves the needle, not just what is urgent. – Marija Zivanovic-Smith, IEX
18. CONCENTRATE ON THREE TO FIVE KEY PRIORITIES RATHER THAN A TASK LIST.
Successful leaders prioritize intentional action. Set clear monthly and weekly goals, solidifying the next week's focus each Friday. Concentrate on three to five key priorities, not just a task list. Review progress weekly, celebrating wins and analyzing roadblocks to proactively address future challenges. – Mukesh Kumar, Slalom
19. STAY PLUGGED IN TO YOUR TEAM'S NEEDS AND OFFER USEFUL FEEDBACK.
Hold weekly one-on-one meetings. A leader who doesn't check in regularly isn't leading—they're guessing. These meetings aren't just status updates; they're where you catch problems early, clear roadblocks, and set clear expectations. Bad managers ignore concerns and fail to provide resources. Good leaders stay plugged in, give direct feedback, and make sure the team is progressing. – Milos Eric, OysterLink
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Los Angeles Times
4 hours ago
- Los Angeles Times
Trump's praise for Sweeney ad sends American Eagle stock surging
American Eagle Outfitters saw its stock price surge more than 20% on Monday, after President Trump praised the retailer's controversial marketing campaign featuring actress Sydney Sweeney on his Truth Social platform. 'Sydney Sweeney, a registered Republican, has the 'HOTTEST' ad out there. It's for American Eagle, and the jeans are 'flying off the shelves.' Go get 'em Sydney!' Trump wrote Monday morning, sparking the rally in shares that began after markets opened. The president's endorsement comes amid a firestorm of criticism over the campaign. The controversy centers on a promotional video featuring Sweeney that was posted to American Eagle's social media channels. The video has since been removed. In the teaser, the 'Euphoria' actress discusses hereditary traits in a sultry voice, stating: 'Genes are passed down from parents to offspring, often determining traits like hair color, personality and even eye color. My jeans are blue.' As she speaks, the video shows Sweeney zipping up her jeans before the camera pans up her body and focuses on her face and blue eyes, framed by blonde hair. The visual emphasis on Sweeney's features prompted backlash from critics on the internet who were quick to accuse the ad of promoting eugenics and aligning with white nationalist messaging. Pittsburgh-based American Eagle defended the campaign in a statement it posted to Instagram last Friday, saying it 'is and always was about the jeans.' Trump used the opportunity to criticize what he called 'woke' advertising, citing examples like Jaguar's recent rebrand and Bud Light's partnership with transgender influencer Dylan Mulvaney in 2023. 'The market cap destruction has been unprecedented, with BILLIONS OF DOLLARS SO FOOLISHLY LOST,' he wrote, contrasting those campaigns with American Eagle's approach. The stock surge represents the latest chapter in what has become a meme-driven rally for American Eagle, which initially jumped last month when retail traders piled into the stock following the campaign's debut. American Eagle has faced significant financial challenges in recent months. In May, the retailer withdrew its full-year guidance and announced a $75-million write-off of spring and summer merchandise due to slow sales, steep discounting and difficult market conditions. The company reported a first-quarter net revenue of $1.1 billion, down 5% from the prior year, with comparable sales falling 3%. Several prominent Republicans, including Vice President JD Vance and Sen. Ted Cruz, have also defended Sweeney and the campaign against criticism. The actress herself has not publicly addressed the controversy surrounding the advertisements. American Eagle shares closed at $13.28 on Monday, up 24%.


Business Upturn
4 hours ago
- Business Upturn
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
– Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis – KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; 'Cyclacel' or the 'Company'), a biopharmaceutical company developing innovative cancer medicines, highlighted a preclinical study from independent investigators titled, ' Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker ' in the journal, Cancer Research, previously reported in a poster at the American Association of Cancer Research 2025 annual meeting.1 The investigators found that several BTC cancer cell lines were sensitive to plogosertib both as monotherapy and in combinations. Consistently with its antimitotic mechanism of action, plogosertib promoted mitotic checkpoint complex (MCC) formation in prometaphase, which induced mitotic arrest resulting in apoptosis of BTC cells. The authors have also found that BUBR1, a critical mitotic checkpoint protein, may be useful as a biomarker to assess plogosertib's effectiveness. BTC cells with high BUBR1 expression were found to be more sensitive to plogosertib compared to those with low expression. The study concluded that BTC cells with high BUBR1 expression are sensitive to the PLK1 inhibitor plogosertib that demonstrate synergistic effects when combined with an ATR inhibitor, which suggest that targeting PLK1 could be an effective strategy for BTC treatment, especially with BUBR1 expression as a potential biomarker to inform optimal combination therapies. About Biliary Tract Cancer (BTC) BTC, also called cholangiocarcinoma, is a rare but aggressive cancer occurring in the biliary tract, a network of small tubes, or ducts, connecting the liver, gallbladder and small intestine. According to estimates from the National Cancer Institute's SEER database annual US incidence of BTC is 4.4 per 100,000. Prognosis for BTC patients is poor with 5-year overall survival of approximately 10–40% even after surgical tumor resection. BTC treatment strategies include chemotherapy, surgery, radiation and targeted medicines depending on location and stage. As these approaches are not curative, there is an urgent, unmet medical need to treat patients with relapsed, refractory and/or unresectable BTC. About Polo-like Kinase and Plogosertib Polo-like kinase 1 (PLK1) is a serine/threonine kinase that plays a central role in cell division or mitosis. PLK1 is an important regulator of the DNA damage cell cycle checkpoint, mitotic entry and exit, spindle formation and cytokinesis, or cell separation into daughter cells. In general, cancer cells, and in particular KRAS mutated and p53(-) cells, are very sensitive to PLK1 depletion. In contrast normal cells with intact cell cycle checkpoints are less sensitive. Pharmacological inhibition of PLK1 in cancer cells blocks proliferation by prolonged mitotic arrest and induces onset of apoptotic death of such cells. Plogosertib (formerly CYC140) is a novel, small molecule, selective and potent PLK1 inhibitor. It has demonstrated impressive efficacy in human tumor xenografts at nontoxic doses. Cyclacel's translational biology program supports the development of plogosertib in solid tumors and leukemias. Preclinical data from independent groups have shown that certain ARID1A- and/or SMARCA-mutated cancers, and cancers associated with DNAJ-PKAc fusions, may benefit from treatment with plogosertib. Additionally, recent data suggest that PLK1 inhibition may be effective in KRAS-mutated metastatic colorectal cancer. PLK1 overexpression correlates with poor patient prognosis in several tumors, including biliary tract, esophageal, fibrolamellar liver, gastric, leukemia, lung, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Initial dose escalation data from a Phase 1 clinical study of oral plogosertib suggest that the compound is well tolerated with no dose limiting toxicity observed in five dosing schedules. Clinical benefit was observed in patients with adenoid cystic, biliary tract, ovarian, and squamous cell sinus cancers. About Cyclacel Pharmaceuticals, Inc. Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle and mitosis biology. The anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit Forward-looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995, and encompasses all statements, other than statements of historical fact contained in this press release. These forward-looking statements can be identified by terminology such as 'may,' 'could,' 'will,' 'expects,' 'anticipates,' 'aims,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'targets,' 'likely to', 'understands' and similar statements. These forward-looking statements are based on management's current expectations. However, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. These statements are neither promises nor guarantees but involve known and unknown risks, uncertainties and other important factors and circumstances that may cause Cyclacel's actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements, including conditions in the U.S. capital markets, negative global economic conditions, potential negative developments resulting from epidemics or natural disasters, other negative developments in Cyclacel's business or unfavorable legislative or regulatory developments. We caution you therefore against relying on these forward-looking statements, and we qualify all of our forward-looking statements by these cautionary statements. For a discussion of additional factors that may affect the outcome of such forward-looking statements, see our 2024 annual report on Form 10-K, and in particular the 'Risk Factors' section, as well as the other documents filed with or furnished to the SEC by Cyclacel from time to time. Copies of these filings are available online from the SEC at or on the SEC Filings section of our Investor Relations website at These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. These forward-looking statements should not be relied upon as representing Cyclacel's views as of any date subsequent to the date of this press release. All forward-looking statements in this press release are based on information currently available to Cyclacel, and Cyclacel and its authorized representatives assume no obligation to update these forward-looking statements in light of new information or future events. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contact Cyclacel Pharmaceuticals, Inc. Email: [email protected] © Copyright 2025 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE: Cyclacel Pharmaceuticals, Inc. 1 Yoojin Jeong, Yoojin Jeong, et al, Abstract 5406: Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker, Cancer Res (2025) 85 (8 Supplement 1): 5406. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
5 hours ago
- Yahoo
Compared to Estimates, Vimeo (VMEO) Q2 Earnings: A Look at Key Metrics
Vimeo, Inc. (VMEO) reported $104.65 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 0.3%. EPS of $0.04 for the same period compares to $0.06 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $105.76 million, representing a surprise of -1.05%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Vimeo performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: ARPU - Self-Serve: $197.00 versus $189.45 estimated by two analysts on average. ARPU - Vimeo Enterprise: $24,705.00 compared to the $25,001.00 average estimate based on two analysts. Revenue- Self-Serve: $57.56 million versus the two-analyst average estimate of $56.4 million. Revenue- Vimeo Enterprise: $25 million versus the two-analyst average estimate of $26.3 million. The reported number represents a year-over-year change of +24.7%. Revenue- Other: $1.63 million compared to the $1.79 million average estimate based on two analysts. The reported number represents a change of -89.6% year over year. Revenue- Add-Ons: $8.2 million versus the two-analyst average estimate of $8.15 million. Revenue- OTT: $12.27 million compared to the $12.05 million average estimate based on two analysts. View all Key Company Metrics for Vimeo here>>> Shares of Vimeo have returned -7.1% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vimeo, Inc. (VMEO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio